Suppr超能文献

纯化的骨骼肌二氢吡啶受体的165-kDa肽段包含钙通道的已知调节位点。

The 165-kDa peptide of the purified skeletal muscle dihydropyridine receptor contains the known regulatory sites of the calcium channel.

作者信息

Sieber M, Nastainczyk W, Zubor V, Wernet W, Hofmann F

出版信息

Eur J Biochem. 1987 Aug 17;167(1):117-22. doi: 10.1111/j.1432-1033.1987.tb13311.x.

Abstract

The dihydropyridine receptor purified from rabbit skeletal muscle yields in the presence of dithiothreitol and sodium dodecyl sulfate on polyacrylamide gels bands of apparent molecular mass 165 +/- 5, 130 +/- 5, 55 +/- 3, 32 +/- 2 and 28 +/- 1 kDa (chi +/- SEM, n = 12). Under nonreducing conditions, the 130 kDa and 28-kDa peptides migrate as a single peptide of 165 kDa. These peptides were separated on a HPLC size-exclusion column. The specific absorption coefficients of the isolated peptides were determined. From these a stoichiometry of 1:1.7 +/- 0.2:1.4 +/- 0.3 (chi +/- SEM of 12 experiments with three different preparations) was calculated for the 165-kDa, 55-kDa and 32-kDa peptides. The relative amount of the 130/28-kDa peptide varied with different preparations. Tryptic, chymotryptic and V-8 protease peptides of the isolated proteins suggested that the 130/28-kDa peptide was not related to the 165-kDa peptide. The dihydropyridine photoaffinity analog (+/-)-azidopine was specifically incorporated only into the 165-kDa peptide with an efficiency of about 2.4%. The azido analog of desmethoxyverapamil, LU 49888, was specifically incorporated into the same peptide with an efficiency of 1.5%. These results suggest that only the 165-kDa peptide contains the regulatory sites detected so far in the voltage-operated L-type calcium channel. They suggest further that the 130/28-kDa peptide, which migrates as a 165-kDa peptide under nonreducing conditions, does not contain high-affinity binding sites for the calcium channel blockers.

摘要

从兔骨骼肌中纯化得到的二氢吡啶受体,在二硫苏糖醇和十二烷基硫酸钠存在的情况下,于聚丙烯酰胺凝胶上呈现出表观分子量分别为165±5、130±5、55±3、32±2和28±1 kDa的条带(χ±标准误,n = 12)。在非还原条件下,130 kDa和28 kDa的肽段以165 kDa的单一肽段形式迁移。这些肽段在高效液相色谱尺寸排阻柱上进行了分离。测定了分离出的肽段的比吸收系数。据此计算出165 kDa、55 kDa和32 kDa肽段的化学计量比为1:1.7±0.2:1.4±0.3(χ±标准误,来自三种不同制剂的12次实验)。130/28 kDa肽段的相对含量因不同制剂而异。分离蛋白的胰蛋白酶、糜蛋白酶和V-8蛋白酶肽段表明,130/28 kDa肽段与165 kDa肽段无关。二氢吡啶光亲和类似物(±)-叠氮平仅以约2.4%的效率特异性地掺入165 kDa肽段中。去甲氧基维拉帕米的叠氮类似物LU 49888以1.5%的效率特异性地掺入同一肽段中。这些结果表明,只有165 kDa肽段包含迄今为止在电压门控L型钙通道中检测到的调节位点。它们还进一步表明,在非还原条件下以165 kDa肽段形式迁移的130/28 kDa肽段不包含钙通道阻滞剂的高亲和力结合位点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验